Sai Life Sciences
Sai Life Sciences Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Sai Life Sciences Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Sai Life Sciences Ltd trades at a P/E of 73.54× and P/B of 10.27×.
Valuation
Profitability
Growth
Financial Health
Sai Life Sciences Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Sai Life Sciences Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Sai Life Sciences Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Sai Life Sciences Ltd, switchable between annual and quarterly views, consolidated or standalone.
Sai Life Sciences Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹25,724.82 Cr and reported EPS of ₹16.41.
| Period | 2025 | 2026 |
|---|---|---|
| Revenue from Operations | 1,695 | 2,192 |
| Other Income | 37 | 49 |
| Total Income | 1,731 | 2,242 |
| Cost of Goods Sold (COGS) | 466 | 571 |
| Gross Profit | 1,229 | 1,622 |
| +Operating Expenses | 823 | 990 |
| EBITDA | 406 | 631 |
| +Non-Operating Expenses | 215 | 198 |
| Profit Before Tax (PBT) | 228 | 466 |
| +Tax Expense | 58 | 117 |
| Profit After Tax (PAT) | 170 | 349 |
| Earnings Per Share (EPS) | 8.16 | 16.48 |
| Diluted Shares Outstanding (Nos.) | 21 | 21 |
| +Additional Disclosures | 1,971 | 2,317 |
| Sales Growth % | — | 29.38 |
| YoY Sales Growth % | — | 29.38 |
| Material Cost % | 27 | 26 |
| Employee Cost % | 32 | 31 |
| Other Cost % | 16 | 14 |
| OPM % | 24 | 29 |
| Tax % | 25 | 25 |
| Profit Growth % | — | 105.08 |
| Gross Margin % | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 |
| Additional Fields | 267 | 464 |
Sai Life Sciences segment analysis: revenue and profit mix.
Disclosed business segments at Sai Life Sciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Sai Life Sciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Sai Life Sciences Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Sai Life Sciences Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Sai Life Sciences Ltd's investment case rests on 10 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Remarkable quarterly profit growth of 548% and sales growth of 77.50%.
Low debt-to-equity ratio of 0.17 provides strong financial stability.
Significant increase in FII and DII holdings reflects growing institutional trust.
Healthy operating profit margin (OPM) of 26.20% showcases efficient cost management.
Demonstrated robust EPS growth of 206.41% over the last three years.
What can break it.
High P/E ratio of 80.12 suggests a significant premium valuation.
ROCE 14.00% and ROE 11.00% are relatively lower than peers.
The company currently offers a 0.00% dividend yield to investors.
Negative annual cash flow per share of -2.65 indicates liquidity concerns.
Slight decrease in promoter holding to 34.9% could raise minor concerns.
What would change my mind.
Trim if P/E re-rates above 96. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 12.11. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 10%. The operating engine is no longer compounding capital efficiently.
Sai Life Sciences Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Sai Life Sciences Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Sai Life Sciences Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Sai Life Sciences Ltd — derived from the live tape, not yesterday's close.
Sai Life Sciences Ltd last traded at ₹1,216.4 with an intraday range of ₹1,206.1–₹1,238.9 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1216.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1300.43 | +84.03 | +6.91% |
| R3 | 1267.63 | +51.23 | +4.21% |
| R2 | 1253.27 | +36.87 | +3.03% |
| R1 | 1234.83 | +18.43 | +1.52% |
| PIVOT | 1220.47 | 4.07 | 0.33% |
| CURRENT | 1216.40 | — | — |
| S1 | 1136.43 | -79.97 | -6.57% |
| S2 | 1169.23 | -47.17 | -3.88% |
| S3 | 1187.67 | -28.73 | -2.36% |
| S4 | 1202.03 | -14.37 | -1.18% |
SAILIFE is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: 1206.1 ~ 1232
Trading Inside opening range
Sai Life Sciences Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Sai Life Sciences Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Sai Life Sciences Ltd stood at 50.5% of traded volume, against a 20-day average of 50.3%.
Sai Life Sciences announcements: results, concalls, ratings, M&A.
Filings Sai Life Sciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Sai Life Sciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 195 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Sai Life Sciences Limited has informed the Exchange about Schedule of meeting with analyst / Investor on 3rd and 4th June 2026 at Mumbai
Analysts/Institutional Investor Meet/Con. Call Updates
Sai Life Sciences Limited has informed the Exchange about Transcript of Earnings Call for the Audited Financial Results of the Company for the…
ESOP/ESOS/ESPS
Sai Life Sciences Limited has informed the Exchange regarding Allotment of 92000 Shares under ESOP Schemes of the Company.
Monitoring Agency Report
Monitoring Agency Report for the quarter and year ended 31 March 2026
Investor Presentation
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
Investor decks & rating reports.
Sai Life Sciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Sai Life Sciences as reported to SEBI — buying and selling signals from the people who know the business best.
Sai Life Sciences insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| TUNER GHOSH | Insider | 21 Feb 2025 | sell | −71.1 K | ₹5.07 Cr | ₹713.07 |
Sai Life Sciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Sai Life Sciences has declared, sequenced by announce and record date.
Sai Life Sciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Sai Life Sciences Ltd: business, sector, key facts.
What Sai Life Sciences Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Sai Life Sciences Ltd operates in the Healthcare, listed as NSE: SAILIFE, BSE: 544306.
Sai Life Sciences Limited is a prominent Contract Research, Development, and Manufacturing Organization (CRDMO) with a global reach, headquartered in Hyderabad, India. Established in 1999 (and formerly known as SAI Advantium Pharma Limited until 2006), the company provides a comprehensive suite of services across the entire drug development lifecycle, from initial research to final manufacturing.
The core business of Sai Life Sciences centers around offering a wide range of services to pharmaceutical and biotechnology companies. These services encompass crucial aspects of drug development and production. Their expertise lies in medicinal chemistry, a critical area for designing and synthesizing new drug molecules. They also possess significant capabilities in pharmacokinetics (PK), the study of how drugs are absorbed, distributed, metabolized, and excreted by the body, which is crucial for determining optimal dosage and safety profiles.
Furthermore, Sai Life Sciences plays a vital role in the manufacturing process, handling the large-scale production of active pharmaceutical ingredients (APIs) and other drug substances. This aspect is crucial for bringing new medicines to the market. In addition to manufacturing, the company offers contract development services, assisting clients with the intricate process of developing their drugs from the laboratory to commercial production. This includes process development, analytical method development and validation, and regulatory support.
In essence, Sai Life Sciences acts as a comprehensive partner for pharmaceutical and biotechnology firms, offering a one-stop solution for many of their research, development, and manufacturing needs. This integrated approach allows clients to streamline their operations, reduce costs, and accelerate the development and launch of new drugs. Their broad service offering and global presence position them as a key player in the contract research and manufacturing landscape.
Questions investors ask about Sai Life Sciences Ltd (SAILIFE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Sai Life Sciences Ltd (SAILIFE)?
The current share price of Sai Life Sciences Ltd (SAILIFE) is ₹1,216.4. Today, the stock has gained by ₹9.60 (0.80%), trading in a range of ₹1,206.1 to ₹1,238.9. The stock opened at ₹1,206.1 with a trading volume of 4,68,762 shares.
02Is Sai Life Sciences Ltd stock a good investment for long-term?
Sai Life Sciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹25,724.82 crores, P/E ratio of 73.54, ROE of 15.13%, and ROCE of 14.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Sai Life Sciences Ltd stock?
The 52-week high price of Sai Life Sciences Ltd (SAILIFE) is ₹1,244.2, while the 52-week low is ₹716.6. Currently trading at ₹1,216.4, the stock is 94.7% away from its 52-week low and 2.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Sai Life Sciences Ltd stock at the current price?
Whether to buy Sai Life Sciences Ltd stock at ₹1,216.4 depends on multiple factors. The stock is currently trading with a P/E ratio of 73.54 and P/B ratio of 10.27. Today's performance shows a gain of 0.80%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Sai Life Sciences Ltd and when is the next dividend?
Sai Life Sciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,216.4, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Sai Life Sciences Ltd?
Sai Life Sciences Ltd's key financial metrics include: P/E Ratio: 73.54, P/B Ratio: 10.27, ROE: 15.13%, ROCE: 14.00%, Dividend Yield: 0.00%, EPS: ₹16.41, Book Value: ₹117.47, and Debt-to-Equity: 11.61. The company's market cap stands at ₹25,724.82 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Sai Life Sciences Ltd stock performing today in the market?
Sai Life Sciences Ltd stock opened at ₹1,206.1 and is currently trading at ₹1,216.4, showing a gain of ₹9.60 (0.80%). The intraday high is ₹1,238.9 and low is ₹1,206.1. The trading volume stands at 4,68,762 shares, indicating moderate market participation today.
08What is the P/E ratio of Sai Life Sciences Ltd and what does it indicate?
Sai Life Sciences Ltd has a Price-to-Earnings (P/E) ratio of 73.54, which means investors are willing to pay ₹73.54 for every ₹1 of earnings. With an EPS of ₹16.41, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Sai Life Sciences Ltd (SAILIFE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy